Nippon Shinyaku

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nippon Shinyaku's Japan sales performance.

Biosimilar Remicade reaches market in Japan and India

Biosimilar Remicade reaches market in Japan and India. Nippon Kayaku’ s version of arthritis drug was approved in July. ... In Japan, Nippon Kayaku has launched a biosimilar version of Remicade (infliximab) originally developed by South Korean

Deal Watch table for September 2013

50. 5. Shin Nippon Biomedical / Transcept Pharma. Licence. TO-2070 nasal powder for acute migraine.

First biosimilar mAb gets the nod in EU

In Japan the drug will be co-marketed by Celltrion's development partner Nippon Kayaku.

New formulations of Pralia and Enbrel head list of new drugs in Japan

The established version of the drug contained 40mg telmisartan and the same dose of amlodipine, and the line extension - which like its predecessor will be co-promoted by Nippon Boehringer Ingelheim -

Result pages: 1 | 2 | 3 | 4 (Next 4)

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

Featured jobs

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Medical Writers: Competitive Salary and Benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Associate Editorial Director – Med Comms – London: Salary TBC

Senior Systematic Review Analyst - Oxford: Negotiable

Events Manager – Med Comms – Surrey: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Medical Writer: Great salary and benefits

Consumer Health Account Director: Circa £60, 000 Gym and More

Medical Writers Required – Cheshire: DOE

Consultant Health Economics - London / Oxford: Negotiable

Senior Medical Writer (Remote Working): Competitive Salary Offered

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Associate Director, Market Access & HEOR – North-West: Negotiable

Associate Director: £75, 000-90, 000

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Scientific Director / Editorial Team Leader: Great salary and benefits

Account Director: £48, 000 - £60, 000

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Director: Excellent benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Director, Market Access / HEOR - North-West: Negotiable

New Business Director - PR: Competitive Salary and benefits

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...